Zantac (Ranitidine)

The Zantac (ranitidine) docket, built on claims that the popular heartburn medication can degrade into a probable carcinogen (NDMA) under certain storage and metabolic conditions and is linked to a range of cancer diagnoses, carries 847 pending federal actions six years after centralization — figures that sit alongside a broader litigation landscape that has also included significant state-court activity outside the federal MDL. That dual federal-and-state structure is an important starting point for any funder, since claim strength and procedural posture can differ meaningfully depending on which court system a given claim is proceeding in and what expert evidence has been admitted there.

For a funder or portfolio-finance allocator, diligence on Zantac claims needs to move past the docket's aggregate size and focus on the specific cancer diagnosis alleged, the individual's dosing and duration history, and — critically — the current state of expert-causation admissibility in the specific court where a given claim sits, since causation rulings in this litigation have not been uniform across venues. That variability is more central to underwriting a Zantac claim than in many single-court mass torts.

Medical-lien considerations are substantial here given that claims typically involve active cancer treatment — chemotherapy, radiation, and surgical intervention — with meaningful associated cost that should be weighed explicitly against expected recovery for any individual claim or portfolio segment.

Given the venue-dependent variability in this litigation, portfolio-level financing should be underwritten with explicit attention to where each claim in the book sits procedurally, rather than treating the docket as a single uniform risk pool. Criterica Capital's mass-tort finance and medical-lien receivables products apply, with pricing calibrated to that venue-specific risk.

Criterica Intelligence's structural brief covers how the federal MDL and parallel state-court proceedings have diverged on causation admissibility.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.